Akero Therapeutics, Inc.
AKRO$1.57T
Mega CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSOUTH SAN FRANCISCO74 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
AKRO News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Efruxifermin | Phase 3 | NASH - Nonalcoholic Steatohepatitis | - | - |
EFX | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply